#atripla

[pozmagazine]

FDA Approves Merck’s Delstrigo and Pifeltro to Treat HIV

The Food and Drug Administration (FDA) has approved Merck’s Pifeltro (doravirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), as well as Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate), which includes Pifeltro in a three-drug, single-tablet antiretroviral (ARV) regimen. Both tablets are indicated for the treatment of HIV among those beginning an ARV regimen for the first time. Pifeltro should be taken in combination with other HIV medications.

[pozmagazine]

HIV Treatment Linked to Faster Kidney Function Decline Among Men

Men living with HIV who are on antiretroviral (ARV) treatment experience faster decline in their kidney function compared with HIV-negative men, aidsmap reports.

Publishing their findings in the journal AIDS, researchers studied data from the Multicenter AIDS Cohort on 917 HIV-positive men on ARVs, 159 HIV-positive men not on ARVs and 1,305 HIV-negative men. The study period ran from October 2003 to September 2014.

[pozmagazine]

Edurant Offers Many Benefits Over Sustiva as First-Line HIV Treatment

Among those starting HIV treatment for the first time, Edurant (rilpivirine) is superior to Sustiva (efavirenz) on multiple measures, aidsmap reports.

Publishing their findings in HIV Medicine, researchers conducted a multicenter, prospective and observational study of 1,490 people with HIV who started their first antiretroviral (ARV) treatment with Edurant (786 people) or Sustiva (704 people) and were members of the Italian Cohort Native Antiretrovirals Foundation Study. All participants began the study with a viral load below 100,000.

[pozmagazine]

FDA OKs Symfi, Mylan’s Third Cut-Price Single-Tablet HIV Regimen

The Food and Drug Administration (FDA) has approved Mylan’s Symfi (efavirenz 600 mg/lamivudine/tenofovir disoproxil fumarate), a single-tablet antiretroviral (ARV) regimen for the treatment of HIV among adults and children who weigh at least 40 kilograms (88 pounds).

[pozmagazine]

FDA Approves Mylan’s Cut-Price HIV Tablets Symfi Lo and Cimduo

The Food and Drug Administration (FDA) has approved two new antiretroviral (ARV) combination tablets, the single-tablet regimen Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) and the two-drug tablet Cimduo (tenofovir disoproxil fumarate/lamivudine). Mylan has indicated that the company intends to offer the tablets at a significant discount compared with the price of similar ARV treatments.

[fundacionluchandovenceras]

ATRIPLA EFAVIRENZ /EMTRICITABINA / FUMARATO DE DISOPROXILO DE TENOFOVIR combinación farmacéutica . . . . . #arv #antiretrovirrales #retrovirrales #atripla #efavirenz #emtricitabina #fumarato #disoproxilo #tenofovir #medicines #medic #medicine #medicinas #medicamento #salud #saludresponsable #saludables https://www.instagram.com/p/CBHNgGZHnd5/?igshid=dxfcz9plmf9a

[fundacionluchandovenceras]

ATRIPLA EFAVIRENZ / EMTRICITABINA / FUMARATO DE DISOPROXILO DE TENOFOVIR #atripla #efavirenz #emtricitabina #fumarato #disoproxilo #tenofovirdisoproxilfumarate #tenofovir #arv #medic #medicine #medicinas #medicamento #retrovirrales #antiretrovirrales #salud #cuidadopersonal #conciencia https://www.instagram.com/p/CA0fLmwjEp2/?igshid=15i0ny083qd4i

[jorgegbordello]

Atripla, 2020.